RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And Uses Thereof
AssigneeAlnylam Pharmaceuticals, Inc.
InventorSailen Barik
Life of this patent
Estimating the term…
Abstract
The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based on these findings, the present invention provides general and specific compositions and methods that are useful in reducing RSV or PIV mRNA levels, RSV or PIV protein levels and viral titers in a subject, e.g., a mammal, such as a human. These findings can be applied to other respiratory viruses.
Claims24
1-15. (canceled)
A method of reducing the levels of an RSV protein, RSV mRNA, or RSV viral titer in a cell in a subject comprising the step of administering an iRNA agent to said subject, wherein the iRNA agent comprises a sense strand having at least 15 contiguous nucleotides complementary to gene P from RSV virus and an antisense strand having at least 15 contiguous nucleotides complementary to said sense strand, wherein said antisense strand comprises 15 or more contiguous nucleotides from a sequence consisting of nucleotides 1 to 19 of SEQ ID NO:
- 6.
An iRNA agent comprising a sense strand and an antisense strand, wherein said sense strand comprises at least 15 contiguous nucleotides complementary to gene P from RSV virus and an antisense strand having at least 15 contiguous nucleotides complementary to said sense strand, wherein said antisense strand comprises 15 or more contiguous nucleotides from a sequence consisting of nucleotides 1 to 19 of SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.